Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
life sciences
national blog main
san francisco blog main
4
×
san francisco top stories
4
×
boston blog main
boston top stories
indiana blog main
indiana top stories
national top stories
raleigh-durham blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
new york blog main
new york top stories
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2019
activism
acute hepatic porphyria
aimmune therapeutics
allergy
alnylam pharmaceuticals
anaphylaxis
andrew oxtoby
avapritinib
bernie sanders
blueprint medicines
boston
What
drug
4
×
therapy
4
×
approval
disease
fda
therapeutics
treat
address
advanced
agency
aimmune
allergy
alnylam’s
approved
approves
awarded
bff
bio
blueprint
building
cancer
carries
certain
conference
deal
deals
designed
developed
developer
devoted
easl
established
firm
form
friday
gene
genetic
immunotherapy
kicked
late
Language
unset
Current search:
drug
×
biotech
×
therapy
×
" san francisco top stories "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed